Skip to content

Trial Summary

The purpose of this study is to determine which of the most commonly used chemotherapy used in recurrent and primary refractory Ewing sarcoma is most beneficial.

Acronym:

rEECur

ACTRN/NCT /ethics:

ACTRN12618001825246

Scientific title:

rEECur: Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

Sponsor / Cooperative group:

ANZCHOG

Trial & Patient Characteristics

Cancer TypeOther
Trial TypeTreatment
PhaseAll phases
Age Range4-50 years old
SexBoth
Tumour Stream Ewing sarcoma
Cancer StageMetastatic or Widespread; Locally Recurrent or Locally Advanced
Anticipated Start Date2014-11-25
Anticipated End Date-

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorNimit Singhal
Recruitment StatusRecruiting